CN102885314A - Novel use of catalpol in health products and foods taken by people suffering from cerebral arterial thrombosis reperfusion injuries - Google Patents
Novel use of catalpol in health products and foods taken by people suffering from cerebral arterial thrombosis reperfusion injuries Download PDFInfo
- Publication number
- CN102885314A CN102885314A CN2011102028116A CN201110202811A CN102885314A CN 102885314 A CN102885314 A CN 102885314A CN 2011102028116 A CN2011102028116 A CN 2011102028116A CN 201110202811 A CN201110202811 A CN 201110202811A CN 102885314 A CN102885314 A CN 102885314A
- Authority
- CN
- China
- Prior art keywords
- catalpol
- health products
- arterial thrombosis
- cerebral arterial
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a novel use of catalpol in health products and foods taken by people suffering from cerebral arterial thrombosis reperfusion injuries and belongs to the technical field of health products and foods. Catalpol can be used in health products and foods taken by people suffering from cerebral arterial thrombosis reperfusion injuries and especially can be used for preparation of health products and foods taken by people suffering from cerebral arterial thrombosis reperfusion injuries and neurologic impairment. The content of catalpol in the health products and the foods is in a range of 1 to 99%.
Description
Technical field
The invention discloses a kind of new purposes of Catalpol, specifically Catalpol belongs to health products, food technology field preparing the health products that are fit to cerebral arterial thrombosis reperfusion injury crowd and take, the application in the food.
Background technology
The cerebral arterial thrombosis sequelae refers to that patients acuity cerebral infarction outbreak leaves over the focal symptoms such as in various degree hemiplegia, aphasia, the slight obstacle of consciousness after the treatment survival.Cerebral apoplexy is common disease and the frequently-occurring disease of harm humans life and health, and there are 1,500 ten thousand patients with cerebral apoplexy in the whole world every year approximately, and wherein cerebral arterial thrombosis occupies sizable ratio (75%-85%).In a large amount of cerebral arterial thrombosis cases of report previously, only small number of patients is recovered fully, and Most patients is residual, and neurological dysfunction is in various degree arranged is the sequelae shape, and main manifestations is the limb motion sensory disturbance.Cerebral arterial thrombosis sequelae shape can follow the patient to continue to increase the weight of until death has brought very large misery to the patient, has also caused very large financial burden to family.But up to now, the cerebral arterial thrombosis sequelae there is no special good effect drug therapy, and comparatively speaking, it is little that Chinese medicine has toxic and side effect, is fit to long-term taking, the advantage that cost is low.Therefore, excavate pools of traditional Chinese medicine, the treatment of innovation cerebral arterial thrombosis sequelae is theoretical, seeks the more efficiently Chinese medicine preparation for the treatment of cerebral arterial thrombosis sequelae, concern extremely both domestic and external.
Catalpol is a kind of iridoid monoglycosides compounds, molecular formula C15H22O10.Catalpol is distributed widely in the plants such as Metachlamydeae, Loganiaceae Lindley Butterflybush Herb genus, Scrophulariaceae bubble Chinese parasol tree genus and glutinous rehmannia genus, bavin Wei section Cinnamomum, Orobanchaceae Cistanche deserticola, Plantaginaceae Plantago, source and abundant.
Summary of the invention
The new purposes that the purpose of this invention is to provide a kind of Catalpol, the health products of namely taking the suitable cerebral arterial thrombosis reperfusion injury crowd of preparation, the application in the food.
The new purposes of above-mentioned Catalpol is preparing the health products that are fit to cerebral arterial thrombosis reperfusion injury companion neurologic impairment symptom crowd and take, the application in the food.
According to the new purposes of above-mentioned Catalpol, be fit to cerebral arterial thrombosis reperfusion injury crowd in preparation, and the cerebral arterial thrombosis reperfusion injury has the health products that neurologic impairment symptom crowd takes, the application in the food, and the content of Catalpol in health products, food is 1-99%.
The present invention is on the basis of existing cerebral ischemia re-pouring injured understanding; adopt line bolt method cerebral ischemia-reperfusion injury in rats model; observe Catalpol to the impact of cerebral ischemia-reperfusion injury in rats neurologic defect function; the result shows: Catalpol administration group can significantly be improved the neurologic defect symptom; obviously improve the beam walking ability; improving grip strength (compares with model group; p＜0.05; p＜0.01); and effect is protected peaceful significantly better than the positive control drug sky; show that Catalpol recovers to have in early days neuroprotection to cerebral ischemia-reperfusion injury in rats; can significantly improve cerebral ischemia neurologic impairment symptom, promote impaired limb motion sensory function to recover.
The specific embodiment
Embodiment 1 is on the impact of neurologic impairment symptom
1.1 purpose
Adopt line bolt method cerebral ischemia-reperfusion injury in rats model, observe Catalpol to the impact of cerebral ischemia-reperfusion injury in rats neurologic defect function, whether have the effect that promotes that cerebral arterial thrombosis sequelae shape recovers to determine it.
1.2 test material
1.2.1 animal
The healthy SD male rat, body weight 240-280g.
1.2.2 medicine
1.2.2.1 be subjected to reagent
Catalpol, white or colourless powder claim the 0.3g powder, and be molten to 100ml with deionized water, gastric infusion 1ml/100g body weight.
1.2.2.2 positive drug
It protects peaceful: Kang Enbei Zhejiang Pharmaceutical Co produces, and clinical every consumption per day is 6.Compound method: get 7 in tablet, pulverizing is dissolved to 100ml with deionized water dissolving, gastric infusion 1ml/100g body weight afterwards.
Butylphenyl phthaleine: Enbipu Pharmacy Co., Ltd., Shiyao Group. produces, and clinical every consumption per day is 0.6g.Compound method: extract 7 capsules contents with syringe, be diluted to 20ml with edible oil, gastric infusion 0.2ml/100g body weight.
1.2.3 main laboratory apparatus
The large mouse grip of YLS-12A tester, science and technology equipment station, Shandong produces.
1.3 method and result
1.3.1 the preparation of cerebral ischemic reperfusion in rats (MCAO) model
The reference literature method is made the MCAO model.Rat is with 10% chloraldurate 0.35g/kg intraperitoneal injection of anesthesia, separate right carotid, internal carotid and external carotid artery, make a kerf in external carotid artery and internal carotid crotch, insert the smooth fishing nylon wire that head end becomes spheroidal from incision, about insertion depth 18-19mm, realize that middle cerebral artery occlusion causes cerebral ischemia.The ligation incision, fixing nylon wire, layer-by-layer suture muscle and skin.Behind the 2h nylon wire head end is extracted nearly incision gently, realize again perfusion.Rats in sham-operated group except embolism arteria cerebri media not, the same ischemia group of remaining processing.
1.3.2 grouping and administration
The rat that nervous symptoms 1-3 is divided is divided into: model group; Catalpol 15mg/kg, 30mg/kg, 60mg/kg administration group; It protects peaceful 0.7/kg positive controls; Edaravone 7mg/kg positive controls.And sham-operation group.3d to 14d gastric infusion behind the ischemic, Edaravone group intraperitoneal injection, sham-operation group and model group give equivalent edible oil gavage and corresponding physiological saline lumbar injection, once a day.
1.3.3 method
1.3.3.1 beam walking experiment
The coordination of beam walking experimental evaluation campaign and integrate damaged.The wide 2.0cm of beam, long 120cm, thick 1.0cm, apart from the unsettled placement of ground 80cm level, beam one end connects a magazine, comes into magazine with the noise stimulation rat by beam.Standards of grading: can not stay on the beam 0 minute; Can stay on the beam but inactive 1 minute; Attempt by, but throw 2 minutes from beam; Walk upper cord, but the hind leg landing number of times of damage was above 50%, 3 minute; Above 1 time but less than 50%, 4 minute; Only landing is 1 time, 5 minutes; Pass through smoothly 6 minutes.Preoperative exercise 5d, once a day, allow all rats comment 6 minutes till.Point detects take ischemic 3,6,9,12,14d as observing time.
1.3.3.2 grip strength test
The size of grip strength test evaluation grip strength.Rat two forelimbs are caught the pulling force cross bar of tension tester, tester's left hand is fixing tension board first, the right hand is held the mouse tail backward, unclamp left hand, right hand reinforcing pulls the rat health backward, and rat is not put in order not grasp cross bar from cross bar slippage meeting, until slippage, read the maximum pull value that makes the rat slippage, survey 2 times, get maximum for every.Point detects take ischemic 3,6,9,12,14d as observing time.
1.4. result
See Table 1-1,1-2,1-3, table 1-4,1-5,1-6.
Table 1-1 Catalpol is on the impact of MCAO rat model nervous symptoms scoring
Annotate: compare * p＜0.05, * * p＜0.01 with model group.
From table 1-1 as seen, rats in sham-operated group does not have the neurologic impairment performance, each ischemia group rat nervous symptoms performance obviously, but gradually the voluntarily recovery along with the prolongation of time, and the resume speed of the neurologic defect of administration group rat is obviously faster than model group, slow down gradually but began its resume speed in 9 days from postoperative, within the observation period, still have the part rat to fail to return to fully normal level.Postoperative 9,12, each administration group of 14d and model group more all have significant difference.
Table 1-2 Catalpol is on the impact of MCAO rat model beam walking ability
Annotate: compare * p＜0.05, * * p＜0.01 with model group.
From table 1-2 as seen, rats in sham-operated group beam walking ability does not change, each ischemia group rat beam walking ability is obviously improved along with the prolongation of time, and the resume speed of the beam walking ability of administration group rat is obviously faster than model group, but still has indivedual rats not return to normal level fully within the observation period.After surgery 9,12,14d, Catalpol 30mg/kg, 60mg/kg group all can promote the recovery of rat locomotor activity, significantly improves (p＜0.05) with the model group scoring of relatively walking; It protects the respectively recovery of after surgery 9d and 12d promotion rat locomotor activity of peaceful group, relatively have significant difference with model group, and 14d all shows the effect that obvious promotion beam walking ability is recovered after surgery.
Table 1-3 Catalpol is on the impact of MCAO rat model grip strength
Annotate: compare * p＜0.05, * * p＜0.01 with model group.
From table 1-3 as seen, the grip strength of Rats after Focal Cerebral Ischemia forelimb significantly reduces, ischemic 9d, and each administration group and model group relatively all can obviously increase the forelimb grip strength of rat, p＜0.05, p＜0.01; Ischemic 14d compares with model group, Catalpol 30mg/kg, 60mg/kg group, day peaceful group of forelimb grip strength that can obviously increase rat of guarantor, p＜0.05.
Table 1-4 Catalpol is on the impact of MCAO rat model nervous symptoms scoring
Annotate: compare * p＜0.05, * * p＜0.01 with model group.
From table 1-4 as seen, rats in sham-operated group does not have the neurologic impairment performance, each ischemia group rat nervous symptoms performance obviously, but gradually the voluntarily recovery along with the prolongation of time, and the resume speed of the neurologic defect of administration group rat is obviously faster than model group, but still has the part rat to fail to return to fully normal level within the observation period.Postoperative 14d, Catalpol group and butylphenyl phthaleine 70mg/kg administration group and model group relatively have significant difference, p＜0.01.
Table 1-5 Catalpol is on the impact of MCAO rat model beam walking ability
Annotate: compare * p＜0.05, * * p＜0.01 with model group.
From table 1-5 as seen, rats in sham-operated group beam walking ability does not change, each ischemia group rat beam walking ability is obviously improved along with the prolongation of time, and the resume speed of the beam walking ability of administration group rat is obviously faster than model group, but still has the part rat not return to normal level fully within the observation period.Postoperative 14d, Catalpol 30mg/kg, 60mg/kg administration group and butylphenyl phthaleine 70mg/kg administration group and model group comparison can obviously promote the recovery of rat beam walking ability, p＜0.05.
Table 1-6 Catalpol is on the impact of MCAO rat model grip strength
Annotate: compare * p＜0.05, * * p＜0.01 with model group.
From table 1-6 as seen, the grip strength of Rats after Focal Cerebral Ischemia forelimb significantly reduces.Ischemic 10,14d, each administration group and model group relatively all can obviously increase the forelimb grip strength of rat, p＜0.05, p＜0.01.
Embodiment 2
Method for making: (1) Catalpol, lactose, pregelatinized starch, sodium dihydrogen phosphate mix
(2) add 60% ethanol 550-800ml and granulate, cross 20 mesh sieves, 60 ℃ of oven dry
The whole grain of (3) 20 mesh sieves, compacting in flakes
Embodiment 3
Method for making: (1) Catalpol, lactose, starch, mix
(2) PVP dissolves with 70% ethanol 450-700ml, adds in (1) to granulate, and crosses 20 mesh sieves, 70 ℃ of oven dry
The whole grain of (3) 20 mesh sieves, compacting in flakes
Embodiment 4
Catalpol 900g
Lactose 97.5g
Dolomol 2.5g
Method for making: (1) Catalpol, lactose mix
(2) 90% ethanol 350-650ml add granulation in (1), cross 24 mesh sieves, 70 ℃ of oven dry
The whole grain of (3) 24 mesh sieves, compacting in flakes
Embodiment 5
Method for making: it is even to get above mixing of materials, records into capsule
Embodiment 6
Method for making: (1) Catalpol, lactose mix
(2) add 60% ethanol 400-600ml and granulate, cross 304 mesh sieves, 70 ℃ of oven dry
The whole grain of (3) 30 mesh sieves is recorded into capsule
Embodiment 7
Method for making: (1) Catalpol, lactose mix
(2) hydroxypropyl methylcellulose is dissolved in 80% ethanol 400-500ml, adds in (1) to granulate, and crosses 24 mesh sieves, 60 ℃ of oven dry
The whole grain of (3) 24 mesh sieves is recorded into capsule.
Claims (3)
1. Catalpol is preparing the health products that are fit to cerebral arterial thrombosis reperfusion injury crowd and take, the application in the food.
2. described according to claim 1, Catalpol is fit to the cerebral arterial thrombosis reperfusion injury in preparation and has the health products that neurologic impairment symptom crowd takes, the application in the food.
3. the application of Catalpol according to claim 1 and 2 in health products, food is characterized in that the content of Catalpol in health products, food is 1-99%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102028116A CN102885314A (en) | 2011-07-20 | 2011-07-20 | Novel use of catalpol in health products and foods taken by people suffering from cerebral arterial thrombosis reperfusion injuries |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102028116A CN102885314A (en) | 2011-07-20 | 2011-07-20 | Novel use of catalpol in health products and foods taken by people suffering from cerebral arterial thrombosis reperfusion injuries |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102885314A true CN102885314A (en) | 2013-01-23 |
Family
ID=47529166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102028116A Pending CN102885314A (en) | 2011-07-20 | 2011-07-20 | Novel use of catalpol in health products and foods taken by people suffering from cerebral arterial thrombosis reperfusion injuries |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102885314A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101250205A (en) * | 2008-03-12 | 2008-08-27 | 谢鹏 | Catalpol and use of its derivatives in preparation of medicine controlling cerebrovascular disease |
| CN101579319A (en) * | 2009-06-12 | 2009-11-18 | 西南大学 | Medical prescription of catalpol freezing-drying powder for injection and preparation method |
| CN102058712A (en) * | 2009-11-13 | 2011-05-18 | 上海玉森新药开发有限公司 | Rehmannia stem and leaf extract and preparation method and application thereof |
-
2011
- 2011-07-20 CN CN2011102028116A patent/CN102885314A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101250205A (en) * | 2008-03-12 | 2008-08-27 | 谢鹏 | Catalpol and use of its derivatives in preparation of medicine controlling cerebrovascular disease |
| CN101579319A (en) * | 2009-06-12 | 2009-11-18 | 西南大学 | Medical prescription of catalpol freezing-drying powder for injection and preparation method |
| CN102058712A (en) * | 2009-11-13 | 2011-05-18 | 上海玉森新药开发有限公司 | Rehmannia stem and leaf extract and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 李杨，等: "梓醇对缺血再灌注受损伤神经元保护作用的研究", 《中国现代医学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2398794T3 (en) | A pharmaceutical composition and its application in the preparation of a medicine for the treatment of cerebrovascular diseases | |
| CN103623071B (en) | A kind of Powerful insect repellent for veterinary use and preparation method thereof | |
| CN103006792B (en) | A kind of herbal medicine for preventing and treating livestock and poultry intestinal canal diseases and preparation method thereof and feed | |
| CN105748543B (en) | A Chinese medicinal composition for treating rheumatic diseases, and its preparation method | |
| CN108853217A (en) | A kind of pharmaceutical composition and its application for treating chicken Mycoplasma synoviae | |
| KR20170142756A (en) | composition and method thereof | |
| KR20140034620A (en) | Composition for preventing or treating diabetbes mellitus disease containing extract of plants | |
| CN108403939A (en) | Treat compound Chinese medicinal preparation and the Chinese medicine composition used of hemorrhoid and constipation | |
| CN1843426B (en) | Chinese medicine composition for treating acute and chronic gastroenteritis and preparing method thereof | |
| CN110664809B (en) | Pharmaceutical composition for preventing and treating cerebral infarction | |
| CN104324250B (en) | A kind of cerebral arterial thrombosis Chinese medicine composition and preparation method thereof | |
| CN102861043A (en) | Application of catalpol in preparation of medicine for treating ischemic cerebral apoplexy sequelae | |
| CN102885838A (en) | Novel use of catalpol in preparation of drug for treating cerebral arterial thrombosis reperfusion injuries | |
| CN102885314A (en) | Novel use of catalpol in health products and foods taken by people suffering from cerebral arterial thrombosis reperfusion injuries | |
| CN102885295A (en) | Novel use of catalpol in health products and foods taken by people suffering from cerebral arterial thrombosis sequelae | |
| ES2576077B1 (en) | Anesthesia solution and its method of application for anesthesia, stunning and fish slaughter | |
| CN108813202A (en) | A kind of feed addictive and production method for poultry expelling parasite | |
| CN102861042A (en) | Novel application of catalpol | |
| CN104257809B (en) | A kind of preparation method who treats constipation Tibetan medicine | |
| CN103585547B (en) | Series of products containing Rhizoma Polypodiodis Nipponicae | |
| CN102885244A (en) | New application of catalpol in health-care product and food | |
| CN104839483A (en) | Mixed feed for soft-shelled turtles of 2-3 years old and preparation method thereof | |
| CN105010878A (en) | Cat food and making method thereof | |
| CN103393891A (en) | Antiviral compound traditional Chinese medicine for animals, and preparation method and use thereof | |
| CN105169240B (en) | A kind of Chinese medicine composition obstructed for stagnation of blood stasis, vascular and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130123 |